Advertisement

Immunogen Inc. (Nasdaq: IMGN) saw its stock rise almost 4 percent Wednesday, after an analyst at New York investment bank Cowen and Co. launched coverage of the stock with an “outperform” or “buy” rating.

Advertisement
Advertisement